Cargando…
Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model
The aim of the present study was to evaluate the effects of the selective cyclooxygenase (COX)-2 inhibitor celecoxib on the development of uterine adenomyosis in mice. ICR neonatal mice were first exposed to tamoxifen to establish a mouse model of adenomyosis. Following 60 days of celecoxib treatmen...
Autores principales: | Jin, Zhixing, Wu, Xiaoyi, Liu, Haiou, Xu, Congjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132242/ https://www.ncbi.nlm.nih.gov/pubmed/32266025 http://dx.doi.org/10.3892/etm.2020.8580 |
Ejemplares similares
-
Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007) -
Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013) -
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
por: Walker, Chris
Publicado: (2018) -
Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
por: Walker, Chris
Publicado: (2019) -
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice
por: Klenke, Frank Michael, et al.
Publicado: (2006)